Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfonso De Simone

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
The FEBS Journal|August 18, 2019
Biochemical and biophysical comparison of human and mouse beta-2 microglobulin reveals the molecular determinants of low amyloid propensityAdnane Achour, Luca Broggini, Xiao Han, et al.
Journal of the American Chemical Society|April 10, 2025
Local Ionic Conditions Modulate the Aggregation Propensity and Influence the Structural Polymorphism of α-SynucleinMaria Zacharopoulou, Neeleema Seetaloo, James Ross, et al.
International Journal of Molecular Sciences|November 17, 2020
Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein OligomersLaura Boi, Augusta Pisanu, Maria Francesca Palmas, et al.
Journal of Neurology|July 10, 2024
Immune responses to oligomeric α-synuclein in Parkinson's disease peripheral blood mononuclear cellsAna Florencia Vega-Benedetti, Clara Porcedda, Tommaso Ercoli, et al.
Cell Death Discovery|November 28, 2025
Retinal alterations resemble brain pathology in a rat model of Parkinson's disease induced by intranigral infusion of α-synuclein oligomersChiara Burgaletto, Anna Flavia Cantone, Maria Francesca Palmas, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-MonothiopomalidomideMaria Francesca Palmas, Khosro Aminzadeh, Matteo Runfola, et al.
Molecular Therapy. Nucleic Acids|April 23, 2026
<b>Broadly cross-reactive mRNA COVID-19 vaccine encoding trimeric RBDs and NSP12 mitigates immune imprinting</b>Arianna De Chiara, Caterina Giachino, Maria Franca Pirillo, et al.
Science Advances|November 5, 2020
Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's diseaseGabriella T Heller, Francesco A Aprile, Thomas C T Michaels, et al.
Cells|September 9, 2022
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate CortexMaria Francesca Palmas, Michela Etzi, Augusta Pisanu, et al.
Human Molecular Genetics|September 12, 2012
Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disordersKatell Peoc'h, Etienne Levavasseur, Emilien Delmont, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
The FEBS Journal|August 18, 2019
Biochemical and biophysical comparison of human and mouse beta-2 microglobulin reveals the molecular determinants of low amyloid propensityAdnane Achour, Luca Broggini, Xiao Han, et al.
Journal of the American Chemical Society|April 10, 2025
Local Ionic Conditions Modulate the Aggregation Propensity and Influence the Structural Polymorphism of α-SynucleinMaria Zacharopoulou, Neeleema Seetaloo, James Ross, et al.
International Journal of Molecular Sciences|November 17, 2020
Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein OligomersLaura Boi, Augusta Pisanu, Maria Francesca Palmas, et al.
Journal of Neurology|July 10, 2024
Immune responses to oligomeric α-synuclein in Parkinson's disease peripheral blood mononuclear cellsAna Florencia Vega-Benedetti, Clara Porcedda, Tommaso Ercoli, et al.
Cell Death Discovery|November 28, 2025
Retinal alterations resemble brain pathology in a rat model of Parkinson's disease induced by intranigral infusion of α-synuclein oligomersChiara Burgaletto, Anna Flavia Cantone, Maria Francesca Palmas, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-MonothiopomalidomideMaria Francesca Palmas, Khosro Aminzadeh, Matteo Runfola, et al.
Molecular Therapy. Nucleic Acids|April 23, 2026
<b>Broadly cross-reactive mRNA COVID-19 vaccine encoding trimeric RBDs and NSP12 mitigates immune imprinting</b>Arianna De Chiara, Caterina Giachino, Maria Franca Pirillo, et al.
Science Advances|November 5, 2020
Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's diseaseGabriella T Heller, Francesco A Aprile, Thomas C T Michaels, et al.
Cells|September 9, 2022
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate CortexMaria Francesca Palmas, Michela Etzi, Augusta Pisanu, et al.
Human Molecular Genetics|September 12, 2012
Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disordersKatell Peoc'h, Etienne Levavasseur, Emilien Delmont, et al.
Pageof 15